Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized CAR-T for Recurrent Malignant Gliomas
NCT03423992Phase 1Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Mar 2018
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA in malignant glioma, sponsored by Xuanwu Hospital. Primary endpoint: Adverse events attributed to the administration of the chimeric antigen receptor T cells at 1 year. Status: unknown.
02
Drugs
CART-BCMA
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03423992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423992.